Given the lack of comprehensive and up to date information on the frequency of KRAS G12C and its characteristics of presentation, our group reviewed data from a large cohort of CRC and NSCLC samples (almost 10 thousand samples overall) submitted to KRAS testing in a clinical certified laboratory. This evidence concerns the gene KRAS and non-small cell lung carcinoma.